Olezarsen Shows Triglyceride Reduction in Phase 3 Balance Study by Ionis Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals announced positive topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome. The trial met its primary efficacy endpoint with a significant reduction in triglyceride levels and a 100% reduction in acute pancreatitis events compared to placebo.
September 26, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive results from Ionis Pharmaceuticals' Phase 3 Balance study of olezarsen could boost investor confidence and potentially lead to an increase in the company's stock price.
The successful Phase 3 trial results for olezarsen, a drug developed by Ionis Pharmaceuticals, could lead to increased investor confidence in the company. This could potentially result in an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100